Risiko Perdarahan Saluran Cerna pada Pasien COVID-19 berdasarkan Jenis Obat Antivirus di Rumah Sakit Umum Pusat Dr. M. Djamil Padang
Coronavirus disease 2019 (COVID-19) has become a global pandemic to date. Some studies reported gastrointestinal tract (GIT) bleeding occurs in several patients hospitalized with COVID-19. Medications known to be associated with an increased risk of GIT bleeding were not associated with GIT bleeding...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Faculty of Medicine at Universitas Andalas
2022-12-01
|
| Series: | Jurnal Kesehatan Andalas |
| Online Access: | http://jurnal.fk.unand.ac.id/index.php/jka/article/view/2042 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557832531083264 |
|---|---|
| author | Arnelis Arnelis Saptino Miro Nasrul Zubir Vesri Yoga Andry Kurniawan Alexander Kam Abdul Alim Rahimi Jersivindo Ranazeri R. Ifan Arief Fahrurozi |
| author_facet | Arnelis Arnelis Saptino Miro Nasrul Zubir Vesri Yoga Andry Kurniawan Alexander Kam Abdul Alim Rahimi Jersivindo Ranazeri R. Ifan Arief Fahrurozi |
| author_sort | Arnelis Arnelis |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) has become a global pandemic to date. Some studies reported gastrointestinal tract (GIT) bleeding occurs in several patients hospitalized with COVID-19. Medications known to be associated with an increased risk of GIT bleeding were not associated with GIT bleeding in COVID-19 patients. Objectives: To examined the risk of gastrointestinal tract (GIT) bleeding in COVID-19 patients based on antiviral drugs at Dr. M. Djamil General Hospital Padang. Methods: A nested cohort study was conducted in Dr. M. Djamil General Hospital Padang from May until October 2021. All COVID-19 patients who received antiviral drugs with GIT bleeding with onset days 0 - 7 were included. COVID-19 was confirmed by RT-PCR swab. Data entry and analysis were conducted by computerized. Results: 30 patients were involved in this study. 43,3% COVID-19 Moderate stage and 56,7% Severe stage. 63,3% were treated with remdesivir and 36,7% were treated with favipiravir. Onset on GIT tract bleeding at day 4 (23,3%), day 5 (26.7%), day 6 (30%), and day 7 (20%). The Chi-square test to determine the factors associated with GIT bleeding in COVID-19 patients including COVID-19 severity, type of antiviral drugs, anticoagulant, and corticosteroid revealed that none of all potential factors above related to GI bleeding. Conclusion: The type of antiviral drugs was not related to GIT bleeding in COVID-19 patients.
Keywords: antiviral drugs, COVID-19, gastrointestinal tract bleeding |
| format | Article |
| id | doaj-art-678f4c7b10ff47f0b701d9f642e89677 |
| institution | Kabale University |
| issn | 2301-7406 2615-1138 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Faculty of Medicine at Universitas Andalas |
| record_format | Article |
| series | Jurnal Kesehatan Andalas |
| spelling | doaj-art-678f4c7b10ff47f0b701d9f642e896772025-02-03T02:11:03ZengFaculty of Medicine at Universitas AndalasJurnal Kesehatan Andalas2301-74062615-11382022-12-01112727810.25077/jka.v11i2.20421217Risiko Perdarahan Saluran Cerna pada Pasien COVID-19 berdasarkan Jenis Obat Antivirus di Rumah Sakit Umum Pusat Dr. M. Djamil PadangArnelis Arnelis0Saptino Miro1Nasrul Zubir2Vesri Yoga3Andry Kurniawan4Alexander Kam5Abdul Alim Rahimi6Jersivindo Ranazeri7R. Ifan Arief Fahrurozi8Gastroenterohepatology Subdivision, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaGastroenterohepatology Subdivision, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaGastroenterohepatology Subdivision, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaGastroenterohepatology Subdivision, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaGastroenterohepatology Subdivision, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaEndocrinology and Metabolic Subdivision, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, IndonesiaCoronavirus disease 2019 (COVID-19) has become a global pandemic to date. Some studies reported gastrointestinal tract (GIT) bleeding occurs in several patients hospitalized with COVID-19. Medications known to be associated with an increased risk of GIT bleeding were not associated with GIT bleeding in COVID-19 patients. Objectives: To examined the risk of gastrointestinal tract (GIT) bleeding in COVID-19 patients based on antiviral drugs at Dr. M. Djamil General Hospital Padang. Methods: A nested cohort study was conducted in Dr. M. Djamil General Hospital Padang from May until October 2021. All COVID-19 patients who received antiviral drugs with GIT bleeding with onset days 0 - 7 were included. COVID-19 was confirmed by RT-PCR swab. Data entry and analysis were conducted by computerized. Results: 30 patients were involved in this study. 43,3% COVID-19 Moderate stage and 56,7% Severe stage. 63,3% were treated with remdesivir and 36,7% were treated with favipiravir. Onset on GIT tract bleeding at day 4 (23,3%), day 5 (26.7%), day 6 (30%), and day 7 (20%). The Chi-square test to determine the factors associated with GIT bleeding in COVID-19 patients including COVID-19 severity, type of antiviral drugs, anticoagulant, and corticosteroid revealed that none of all potential factors above related to GI bleeding. Conclusion: The type of antiviral drugs was not related to GIT bleeding in COVID-19 patients. Keywords: antiviral drugs, COVID-19, gastrointestinal tract bleedinghttp://jurnal.fk.unand.ac.id/index.php/jka/article/view/2042 |
| spellingShingle | Arnelis Arnelis Saptino Miro Nasrul Zubir Vesri Yoga Andry Kurniawan Alexander Kam Abdul Alim Rahimi Jersivindo Ranazeri R. Ifan Arief Fahrurozi Risiko Perdarahan Saluran Cerna pada Pasien COVID-19 berdasarkan Jenis Obat Antivirus di Rumah Sakit Umum Pusat Dr. M. Djamil Padang Jurnal Kesehatan Andalas |
| title | Risiko Perdarahan Saluran Cerna pada Pasien COVID-19 berdasarkan Jenis Obat Antivirus di Rumah Sakit Umum Pusat Dr. M. Djamil Padang |
| title_full | Risiko Perdarahan Saluran Cerna pada Pasien COVID-19 berdasarkan Jenis Obat Antivirus di Rumah Sakit Umum Pusat Dr. M. Djamil Padang |
| title_fullStr | Risiko Perdarahan Saluran Cerna pada Pasien COVID-19 berdasarkan Jenis Obat Antivirus di Rumah Sakit Umum Pusat Dr. M. Djamil Padang |
| title_full_unstemmed | Risiko Perdarahan Saluran Cerna pada Pasien COVID-19 berdasarkan Jenis Obat Antivirus di Rumah Sakit Umum Pusat Dr. M. Djamil Padang |
| title_short | Risiko Perdarahan Saluran Cerna pada Pasien COVID-19 berdasarkan Jenis Obat Antivirus di Rumah Sakit Umum Pusat Dr. M. Djamil Padang |
| title_sort | risiko perdarahan saluran cerna pada pasien covid 19 berdasarkan jenis obat antivirus di rumah sakit umum pusat dr m djamil padang |
| url | http://jurnal.fk.unand.ac.id/index.php/jka/article/view/2042 |
| work_keys_str_mv | AT arnelisarnelis risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang AT saptinomiro risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang AT nasrulzubir risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang AT vesriyoga risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang AT andrykurniawan risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang AT alexanderkam risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang AT abdulalimrahimi risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang AT jersivindoranazeri risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang AT rifanarieffahrurozi risikoperdarahansalurancernapadapasiencovid19berdasarkanjenisobatantivirusdirumahsakitumumpusatdrmdjamilpadang |